Using an online questionnaire, the researchers surveyed patients about their satisfaction with their current medication, the level of stress caused by their IBS-C and their overall acceptance of IBS-C ...

Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults PRESS RELEASE GlobeNewswire ...

Lacy BE. Tenapanor treatment success for IBS-C symptoms increases with duration of therapy. Presented at: ACG Annual Scientific Meeting; Oct. 20-25, 2023; Vancouver, British Columbia (hybrid meeting).

Diarrhea Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients.

When you have irritable bowel syndrome with constipation (IBS-C), pooping can be a pain in more ways than one. Fortunately, there are several at-home strategies you can use to help increase what ...

Irritable bowel syndrome (IBS) is a prevalent gastrointestinal condition, estimated to affect about one in 10 people globally. A new study suggests that dietary interventions may be more effective ...

DEAR DR. ROACH: I’m a young adult male who has been diagnosed with irritable bowel syndrome with constipation (IBS-C). Until this diagnosis, I had never even heard of the condition.

Poster #Tu1658, entitled “Efficacy of Tenapanor in Patients with Irritable Bowel Syndrome with Constipation (IBS-C): A Post Hoc Analysis of Patients with and Without Prior Use of Other IBS-C ...

Poster #Tu1658, entitled “Efficacy of Tenapanor in Patients with Irritable Bowel Syndrome with Constipation (IBS-C): A Post Hoc Analysis of Patients with and Without Prior Use of Other IBS-C ...